Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 14, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress

BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 02, 2022 14:15 ET | Source: Athira Pharma, Inc.

Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Active metabolite of fosgonimeton (ATH-1017) enhances the HGF/MET system, resulting in neurotrophic and procognitive effects In two unique disease models, ATH-1020 reduces depression-like...
February 22, 2022 07:05 ET | Source: Athira Pharma, Inc.

Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models First presentation of preclinical data from ATH-1020 candidate for...
February 22, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease

Fosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer’s disease patients Fosgonimeton was...
January 31, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
January 25, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
January 05, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Provides 2022 Pipeline Outlook

Topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 LIFT-AD Phase 3 Alzheimer’s disease study sample size increased to strengthen statistical power of co-key secondary endpoints and...
November 10, 2021 16:05 ET | Source: Athira Pharma, Inc.

Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

– Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 – – Presented program updates...
November 10, 2021 11:50 ET | Source: Athira Pharma, Inc.

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference

– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira...